NCT05177133 - Anti-PD-1 and CapOx for the First-line Treatment of dMMR Esophagogastric Cancer (AuspiCiOus) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 5, 2021

Primary Completion Date

May 1, 2025

Study Completion Date

November 4, 2029

Conditions

Gastric AdenocarcinomaEsophageal Adenocarcinoma

Interventions

DRUG

Capecitabine

PO Capecitabine

DRUG

Oxaliplatin

IV Oxaliplatin

DRUG

Retifanlimab

IV retifanlimab

Trial Locations (8)

RECRUITING

Academic Medical Center, Medical Oncology, Amsterdam

RECRUITING

Amsterdam UMC, location VUmc, Amsterdam

RECRUITING

Catharina ziekenhuis, Eindhoven

NOT_YET_RECRUITING

Medisch Centrum Leeuwarden, Leeuwarden

NOT_YET_RECRUITING

LUMC, Leiden

RECRUITING

Radboud UMC, Nijmegen

NOT_YET_RECRUITING

Erasmus MC, Rotterdam

RECRUITING

UMC Utrecht, Utrecht